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Abstract
We report on results from whole-exome sequencing (WES) of 1,039 subjects diagnosed with autism spectrum disorders
(ASD) and 870 controls selected from the NIMH repository to be of similar ancestry to cases. The WES data came from two
centers using different methods to produce sequence and to call variants from it. Therefore, an initial goal was to ensure the
distribution of rare variation was similar for data from different centers. This proved straightforward by filtering called
variants by fraction of missing data, read depth, and balance of alternative to reference reads. Results were evaluated using
seven samples sequenced at both centers and by results from the association study. Next we addressed how the data and/
or results from the centers should be combined. Gene-based analyses of association was an obvious choice, but should
statistics for association be combined across centers (meta-analysis) or should data be combined and then analyzed (mega-
analysis)? Because of the nature of many gene-based tests, we showed by theory and simulations that mega-analysis has
better power than meta-analysis. Finally, before analyzing the data for association, we explored the impact of population
structure on rare variant analysis in these data. Like other recent studies, we found evidence that population structure can
confound case-control studies by the clustering of rare variants in ancestry space; yet, unlike some recent studies, for these
data we found that principal component-based analyses were sufficient to control for ancestry and produce test statistics
with appropriate distributions. After using a variety of gene-based tests and both meta- and mega-analysis, we found no
new risk genes for ASD in this sample. Our results suggest that standard gene-based tests will require much larger samples
of cases and controls before being effective for gene discovery, even for a disorder like ASD.
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Introduction
Common and rare variants are important constituents of the
genetic architecture of Autism Spectrum Disorders (ASD) [1–12].
Nonetheless analysis of rare variants has produced the vast
majority of findings that implicate certain genes as playing a role in
liability for ASD (i.e., ASD genes). Because of the promise of
identifying novel ASD genes via rare variants, and the potential
downstream implications regarding treatment, an ambitious
exome sequencing study has been implemented including nearly
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2000 case and control subjects sequenced at two genomic centers.
Exome sequencing studies of complex traits have shown success in
candidate gene studies [13–18]; however, most published candi-
date gene studies have not reported a p-value small enough to
attain exome-wide significance [19].
For rare variants, even if effects are strong, single variant tests
typically have little power. Rare variants have to be combined in
some way, such as within a gene or across genes, for an association
test to reach sufficient power. Hence statistical tests examine the
cumulative effects over the observed rare variants in the target set.
A number of statistical methods to test for association with rare
variants are now available. Several of these tests fall into the
category of burden tests in that they assess association with a
‘‘super-variant’’ [20–24]. Each of these burden methods assumes
variants impact the phenotype in a common direction. Rather
than aggregating variants, another class of methods, including C-
alpha [25] and SKAT [26], look for an unusual distribution of rare
variation among cases and controls.
Power of the test is determined by the number of causal variants
in the gene, the size of the corresponding effects, and the sample
size. Assuming that the rarest variants are likely to have the largest
effects, it is challenging to amass substantial evidence for
association without a large sample size. Based on extrapolation
of effect sizes and frequencies from published studies [19], the
results indicate that thousands of individuals are required to obtain
genome wide significance.
In this ARRA autism sequencing consortium (AASC) study,
data have been produced by two sequencing centers (Baylor
College of Medicine and Broad Institute) and by different exome
capture methods, different sequencing platforms and different pre-
processing alignment and variant calling methods. Therefore the
coverage and quality of these data sets varies. Nonetheless, as we
show in the sequel, these data can be harmonized using standard
filtering criteria. Given the distinct data sources, the most effective
way of testing for association is unclear. Following in the tradition
of association studies, meta-analysis is a natural option [27]. With
this approach we can perform the analysis on each data set
separately and then combine p-values using the weighted Z-score
method. Alternatively, after filtering to homogenize data, we can
combine the two data sets directly and perform mega-analysis.
Meta-analysis has the advantage of permitting and adjusting for
heterogeneity between samples [28]. All other things being equal,
this is the preferred choice. On the other hand, if the power of
mega-analysis is better, then this option is worth pursuing. In this
report we show that mega-analysis is the more powerful procedure
for gene-based tests, such as SKAT [26], a result that might be
counter-intuitive given the well-known efficiency of meta-analysis
for tests of linear form such as logistic regression. For these data we
also find that population structure appears to be corrected for by
using principal components analysis [29].
After quality control and controlling for ancestry, analysis of
AASC data reveals no clear-cut associations, including associations
in known ASD genes. We conclude that rare variants affecting risk
are not clustering in a small number of genes, supporting recent
results from de novo single nucleotide and copy number studies
showing that hundreds of genes in the genome affect risk for ASD
[4–6,8].
Results
Harmonizing Calls of Genotype across Sequencing
Platforms
The AASC whole-exome sequencing data included 1039 ASD
subjects of European ancestry and 870 controls of similar ancestry.
Approximately half of the samples were sequenced using the Solid
platform and called with AtlasSNP 2 [30] (Baylor: 505 cases, 491
controls) and the remainder were sequenced using the Illumina
platform and called with GATK [31] (Broad: 534 cases, 379
controls).
We considered 6 filters to make these data sets more similar in
terms of the distribution of variants in the exome. Filters were
sequential in their stringency for including a variant: Filter PASS
included variants that pass the baseline filter of GATK; Filter
MISS excluded any variant with more than 10% missingness;
Four additional filters placed increasingly stringent requirements
on depth and balance of reference and alternative allele calls (see
Methods). If not otherwise stated, results for analyses were based
on the least stringent of these: Filter DpBal, which filters by
missingness v10%, depth w10, balance v0:75 for Broad and
v0:85 for Baylor.
Seven control samples were sequenced by both centers,
facilitating an independent comparison of cross platform calls
and an evaluation of the filtering process. To do so, we identified
all rare (v1%), non-synonymous variants located in at least one of
the two data sets. Using Filter PASS, in total, these seven samples
had 337,478 calls and only .039% of them were mismatched. With
Filter DpBal, 290,426 calls remained and .017% of them were
mismatched (Table S1). Of the heterozygotes called by one center,
but not the other, the mismatch rate was not symmetric: 9
heterozygotes were called by Baylor, but not by Broad, while 42
heterozygotes were called by Broad, but not by Baylor. On closer
inspection, many of these heterozygotes did appear to be present;
however, one of the variant callers was not confident enough to
make the call. Application of the stricter filters (B–D) led to the
removal of many of the heterozygous calls for which the callers
matched without further improvement in the mismatch rate. For
instance, with Filter D only 65% of the matching heterozygous
calls from Filter PASS were preserved compared to 85% for Filter
DpBal.
Post filtering, the Broad and Baylor data sets had similar
numbers of minor allele calls per sample per gene (Figure 1A). The
Baylor variant count was slightly greater than the Broad count
(Figure 1B), due in part to the larger number of samples in the
Author Summary
This study evaluates association of rare variants and autism
spectrum disorders (ASD) in case and control samples
sequenced by two centers. Before doing association
analyses, we studied how to combine information across
studies. We first harmonized the whole-exome sequence
(WES) data, across centers, in terms of the distribution of
rare variation. Key features included filtering called variants
by fraction of missing data, read depth, and balance of
alternative to reference reads. After filtering, the vast
majority of variants calls from seven samples sequenced at
both centers matched. We also evaluated whether one
should combine summary statistics from data from each
center (meta-analysis) or combine data and analyze it
together (mega-analysis). For many gene-based tests, we
showed that mega-analysis yields more power. After
quality control of data from 1,039 ASD cases and 870
controls and a range of analyses, no gene showed exome-
wide evidence of significant association. Our results
comport with recent results demonstrating that hundreds
of genes affect risk for ASD; they suggest that rare risk
variants are scattered across these many genes, and thus
larger samples will be required to identify those genes.
Rare, Exonic Variants Association Study for Autism
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Baylor data set. The average count of rare variants per gene was
9.24 for Baylor and 8.82 for Broad. Association analysis was
limited to non-synonymous variants that had minor allele
frequency (MAF) less than 1%. A total of 156,636 and 152,851
variants were retained in the Baylor and Broad samples,
respectively. After filtering 9,738 and 5,808 indels were retained
in the Baylor and Broad samples, respectively.
Meta- Versus Mega-Analysis
Information from two or more datasets can be combined via
meta-analysis with the weighted Z-score approach [32]. In the
context of the SKAT test this approach assimilates gene-level
information without consideration of the directionality of any
single variant effects. Alternatively, if the data are combined after
careful filtering and harmonization, it is possible to analyze all data
simultaneously using a mega-analysis approach.
For a theoretical comparison of these approaches, see the
Methods; here we provide empirical analysis. To compare
analytically the power of meta- and mega-analysis we assume
two data sets have the same sample size and rare variants at the
same locations. Results of this analysis show that, regardless of the
number of variants, mega-analysis has greater power than meta-
analysis, unless the signal is so strong that both have power close to
one (Figure 2).
More realistic power comparisons can be made based on the
observed Baylor and Broad variant calls directly in simulation. We
focus on the 1090 genes with the largest number of variants to
obtain the greatest flexibility for configurations of causal variants.
From the combined list of variants, some of which are observed
only in Baylor or Broad, but not both, and some of which are
shared, we randomly pick a fraction f as causal variants. We use
causal variants to generate the phenotype based on the model in
Eqn. 1 with odds ratio inversely proportional to allele frequency.
The fraction of rare variants that are causal varies from f~20% to
50%. In the analysis we upweight variants inversely proportional
to allele frequency using SKAT’s default setting. We also use
SKAT to calculate the p-values for Baylor, Broad and the merged
data sets based on its standard approximation technique. For this
simulation analysis and for all our other data analysis, we combine
all singleton variants as a super-variant. For meta-analysis the
weighted Z-score method combines the two p-values from Baylor
and Broad for each gene. Notice that in this analysis, mega-
analysis performs better than meta-analysis under a variety of
different distributions of causal variants and different log odds
ratios (Figure 3).
To gain intuition into the comparison between meta- and mega-
analysis, consider combining information across two dataset of
approximately equal size. If, in the combined sample and for a
particular variant, we observe all of the rare alleles in cases and
none in controls, then the evidence for association is higher than if
we combine statistics in which half of the rare alleles are observed
in cases from each of two sub-samples. For example, for a variant
observed 4 times, twice in cases from both subsamples, the mega
and meta p-values are .06 versus .17, respectively. The difference
in evidence occurs because there are five ways 4 alleles can be
partitioned between cases and controls in the mega dataset (4:0,
3:1, 2:2, 1:3 and 0:4); however, there are only three ways that 2
alleles can be partitioned between cases and controls. Thus with a
larger sample, it is possible for rare alleles to obtain more unusual
configurations. As variants become extremely rare the situation
becomes more unfavorable to meta-analysis. Unless the sample is
very large, most samples will draw only one copy of the rare allele
and in this scenario neither of the two case-control configurations
is unusual. With singleton variants SKAT can only gain
information about association if the rare variants are grouped to
form a super-allele.
Alternatively, mega-analysis also has advantages when consid-
ering rare alleles with no effect. If, for a particular variant, we
observe half of the rare alleles in cases and half in controls in the
combined sample, but all of the alleles are in cases in the first
Figure 1. Distribution of rare variants per gene in Baylor and Broad data sets after filtering. Minor allele counts (MAC) are restricted to
variants with minor allele frequencyv1%. Panel (A), distribution of mean MAC per sample, averaged over all genes. Panel (B), in the Baylor samples,
genes were binned based on the counts of rare variants (which range from 1 to 30); for each bin the vertical axis shows the distribution of counts
(boxplot) from the same genes in the Broad samples. The red line indicates an equal count in Broad and Baylor.
doi:10.1371/journal.pgen.1003443.g001
Rare, Exonic Variants Association Study for Autism
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sample and all are in controls in the second sample, then the
evidence for association is appropriately diminished by considering
the full sample simultaneously (for 6 variants, mega~:65 versus
meta~:05). If there were only one variant per gene, it would be
possible to adjust the meta-analysis to capture the sign of the
association and overcome this weaknesses; however, gene-based
statistics rely on having multiple variants per gene to gain power.
With multiple variants, the power differential in mega versus meta
occurs because mega-analysis assimilates information variant by
variant, cancelling out false signals that differ in direction of
association across data sets and capitalizing on true signals that
match in direction. By construction, meta-analysis is restricted to
combining information at the gene level post hoc, rather than at
the variant level. In total, these comparisons explain why mega-
analysis has greater power than meta-analysis for statistical tests
such as C-alpha and SKAT, that are based on the distribution of
rare variants across cases and controls.
Distribution of AASC Data
To evaluate how sensitive the test statistic is to linkage
disequilibrium typical of rare variants, we select 144 genes that
have exactly d = 20 variants in the Broad data set. Using these data
we randomly assigned case-control status to generate a null
distribution for test statistics. With no linkage disequilibrium
structure among rare variants, and appropriately chosen weights,
the score test statistics Q is known to follow a x2d distributions
Figure 2. Theoretical power comparison: Meta versus Mega. Theoretical power functions of meta- (red) and mega-analysis (blue) at
significance level of :0001. c is the strength of signal per variant and d is the number of rare variants. (A) d~15; (B) d~10; (C) d~5; and (D) d~3.
doi:10.1371/journal.pgen.1003443.g002
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under the null hypothesis. Alternatively, notable dependencies
among rare variants result in a statistic that follows a mixture of x2
distributions, with degrees of freedom less than d. Results from
simulations under the null in the form of a Q-Q plot (Figure 4),
show that the independence assumption is a reasonable approx-
imation for these data.
For association analysis of common variants (CVs, MAFw5%)
it is common practice to control for ancestry by regressing out the
most predictive eigen-vectors for ancestry derived from a
representative sample of CVs [29]. To determine if the
distribution of rare variants varied in ancestry space similarly to
CVs, we plot individuals based on their ancestry coordinates [33]
using three sets of single nucleotide variants (SNVs): CVs, low
frequency variants (LFVs, 1%vMAFƒ5%), and both types of
variants (CVs+LFVs). The ancestry coordinates are the eigen-
vectors obtained by applying principle components analysis to
CVs (14,702 CVs used in Baylor and 56,607 CVs used in Broad),
LFVs (8783 LFVs used in Baylor and 29,509 LFVs used in Broad)
and CVs+LFVs respectively. The variants used for PCA have no
missing genotypes. We find that individuals cluster fairly similarly
for CVs versus LFVs in eigen-vector 1, but less so for eigen-vector
2; and individuals cluster almost identically for CVs and
CVs+LFVs (Figure 5 for Broad and Figure S1 for Baylor; notice
that the similarity of clusters observed in CVs is apparent using
EVs 1 and 3 for CVs+LFs). In the subsequent data analysis we
explore the effect of using eigen-vectors from CVs and LFVs to
control for confounding due to population structure.
Cases and controls included in the AASC sample have been
chosen to have matching ancestry based on eigen-vectors derived
from CVs obtained from GWAS genotyping platforms [10].
Examining the distribution of cases (orange) and controls (blue)
from Baylor and Broad plotted versus the top 2 eigen-vectors
calculated from CVs in the exome shows that the samples are
fairly evenly distributed in ancestry space but many of the subjects
on the boundary of the eigenspace are cases (Figure 6). When
combining Baylor and Broad samples into a common eigen-space,
Figure 3. Simulation of power. The empirical power comparisons of SKAT applied to Broad (blue), Baylor (green), and combined via mega- (red)
and meta-analysis (orange). We use causal variants to generate the phenotype based on the model in Eqn. 1 with bi~h log10 (pi). Causal rate is the
fraction of variants with bj=0, which varied from f~20% to 50%. We choose weights
ffiffiffiffiffi
vj
p
~Beta(pj ,1,25) and use SKAT to calculate the p-values for
Baylor, Broad and merged data sets. We combine all singleton variants as a super-variant. For meta analysis, the weighted Z-score method combines
the two p-values from Baylor and Broad for each gene. Panel (A) h~log(5)=3:3 and the significance level is set at .001; in panel (B) h~log(4)=3:3 and
the significance level is set at .01.
doi:10.1371/journal.pgen.1003443.g003
Figure 4. Q–Q plot of simulation tests under the assumption that
linkage disequilibrium among rare variants has little impact on
the distribution of the test statistic. 144 genes are selected from the
Broad data set. Each gene has exactly d rare variants, d~20. For each
gene, we first randomly assign the phenotypes for 913 samples based on
a coin toss, then calculate the test statisticsQ, and corresponding p-value
computed under the assumption that Q*x2d . We repeat this 100 times
per gene, to obtain more than 10,000 p-values.
doi:10.1371/journal.pgen.1003443.g004
Rare, Exonic Variants Association Study for Autism
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it is evident that the two samples overlap substantially (Figure S2).
The Baylor sample, however, includes greater diversity.
As a first step to investigate the distribution of rare variants, we
identify all pairs of individuals who share doubleton variants, i.e.,
each had one copy of an SNV seen only twice in the entire sample.
Doubletons are of interest because they are the rarest variants in
our sample for which we have strong confidence in the variant
calls. When we tally the total number of doubleton variants
possessed by each individual in the Baylor case sample, the
distribution of the doubleton-count varies widely, with some
individuals having a far greater share of these rare variants than
expected due to chance. We examine the distribution of
doubletons as a function of the eigen-map. Figure 7 displays the
relative count of doubletons in the 2-dimensional eigen-map for
the Baylor and Broad samples. Individuals with the largest number
of doubletons tend to be clearly separated from the majority of the
subjects in ancestry space by the top two eigen-vectors.
To compare the distribution of doubleton counts with the
distribution of common variants, for each individual in the Baylor
case sample we tally their count of minor alleles (MAC_c) over
exonic CVs. From Figure 8A, 8B it is clear that individuals with a
large count of doubletons also possess a disproportionate number
of minor alleles, suggesting that these individuals are toward the
boundary of the European ancestry space. Indeed all of these
individuals are separated in eigenspace from the majority of the
individuals (Figure 7A, orange points). Furthermore, sample
records suggest that many of these individuals are from Portugal,
a population whose individuals have a somewhat larger compo-
Figure 5. PCA from common variants, low frequency variants, and both types of variants. Plotted are the first eigen-vector versus second
eigen-vector for Broad samples. Eigen-vectors are obtained by applying PCA to all common variants that have no missingness (56,607 variants) (A), all
low frequency variants that have no missingness (29,509 variants) (B), and both type of variants (C). The colors are obtained by clustering individuals
based on their coordinates in panel (A) using model based clustering [51].
doi:10.1371/journal.pgen.1003443.g005
Figure 6. PCA for case (orange) and control (blue) samples. Panels (A) and (B) plot the top two eigen-vectors for Baylor and Broad,
respectively. Eigen-vectors are obtained by applying PCA to all common variants (CVs) that have no missingness (14,702 CVs used in Baylor and
56,607 CVs used in Broad).
doi:10.1371/journal.pgen.1003443.g006
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nent of African ancestry. The same pattern exists in the Broad case
sample (Figure 7B and Figure 8C); however the Broad sample does
not include any individuals with very large numbers of doubleton
variants.
These findings suggest that the distribution of common variants
might function as a proxy for the distribution of rare variants. Next
we look to see if these descriptive analyses support the use of an
eigen-map to control for confounding in rare variant tests due to
ancestry. To test for association between ASD and rare variants in
the AASC sample, we apply burden tests and SKAT to the filtered
version of the data sets and obtain the p-values of genes in the
Baylor, Broad and combined datasets. We investigate the effects of
population structure by calculating the genomic control inflation
factor l [34] when the test is performed with and without
including 10 eigen-vectors for ancestry obtained from genotypes of
CV [29].
Before comparing choices of eigenvectors, we investigate the
behavior of the genomic control statistic, l, when calculated based
on rare variant test statistics. SKAT has been shown to provide
accurate p-values in the tail of the distribution for moderate sized
samples [26]. Indeed, for these data, we also find that the nominal
p-values appear to be accurate in the tail of the distribution (see
below). The distribution of the p-values across the genome,
however, does not follow the expected uniform distribution (Figure
S3A, S3B). Specifically, for those genes clearly not associated with
the phenotype (p-values w:5) we find that SKAT tends to report
p-values biased downward toward .5, causing an apparent, but
uninteresting inflation in the GC factor. Notably, the algorithm for
Figure 7. Distribution of doubletons as a function of the eigen-map. The first eigen-vector versus second eigen-vector for (A) Baylor and (B)
Broad samples. Eigen-vectors are obtained by applying PCA to all common variants. For each individual, we count the number of doubletons. To
indicate the relative number of doubletons per individual, points are color-coded as follows: black (bottom 25%: fewest doubletons), blue (next 25%),
green (next 25%), and orange (top 25%: most doubletons) within the Baylor and Broad samples, respectively.
doi:10.1371/journal.pgen.1003443.g007
Figure 8. Doubletons counts versus minor allele counts (MAC_c) in common variants (CVs). MAC_c are computed for all variants with
minor allele frequencyw:05. Panel (A) is the doubleton counts of Baylor cases versus MACs of CVs in the exome. Panel (B) is a zoomed in version of
panel (A). Panel (C) is the doubleton counts of Broad cases versus MAC_c of CVs in the exome.
doi:10.1371/journal.pgen.1003443.g008
Rare, Exonic Variants Association Study for Autism
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computing p-values seems to be accurate for smaller p-values; we
do not find a bias in estimate of the first quantile (Figure S3A,
S3B). A similar phenomenon holds true for the burden test, but to
a much lesser extent (Figure S3C, S3D). This is likely due to the
very small counts of rare variants. Using permutations to obtain p-
values would remedy the situation, but at a substantial cost in
computation.
These insights into the null distribution of the rare variant test
statistics lead us to calculate lq, a variant on the GC principle
based on the first quantile (rather than the median) of the p-value
distribution. For a properly calibrated statistic lq has an expected
value of 1 when there is no confounding due to population
structure (see Text S1). To compare the behavior of these two
genomic control factors we conduct the following experiment. We
calculate l and lq based on SKAT statistics computed for the
1000 largest genes. Then we permute case and control status 100
times, computing the genomic control factors for each permuta-
tion, to obtain the distribution of these statistics (Figure 9 and
Figure S4). Notice that the observed value of lq is close to the
mean of the simulated distribution for all 3 choices of eigen-
vectors. In contrast l shows much greater variability and the mean
of the permutation distribution is shifted further above 1,
Figure 9. Distribution of the genomic control factor lq. By permuting case/control status 100 times the distribution of lq is obtained based on
the 1000 largest genes. The red line shows the mean of the permutation distribution and the green line shows lq obtained from the data using (A)
Broad SKAT p-values obtained without eigen-vectors; (B) Broad SKAT p-values, with common variants (CVs) eigen-vectors, (C) Broad SKAT p-values,
with low frequency variants (LFVs) eigen-vectors; and (D) Broad SKAT p-values, with CVs plus LFVs eigen-vectors.
doi:10.1371/journal.pgen.1003443.g009
Rare, Exonic Variants Association Study for Autism
PLOS Genetics | www.plosgenetics.org 8 April 2013 | Volume 9 | Issue 4 | e1003443
supporting our conjecture that l provides a positively biased
estimate of the effect of confounding when using the SKAT
statistic for samples like this one.
Next we examine the effect of adjusting for ancestry (using CVs)
on the rare variant test statistics. Notice that while l is inflated for
all conditions, lq is controlled fairly well in the Baylor and Broad
samples individually (Table 1); in the mega SKAT analysis there is
a slight inflation (lq~1.08). From Table 1 and from the -
log10(observed p-values) versus -log10(expected p-values) plot
(Figure 10) we see the distribution of the test statistics follows the
null hypothesis quite closely. We conclude that adjusting for
ancestry using CVs is sufficient to yield a substantial reduction in
lq.
We explore this further by contrasting the results obtained when
applying no correction versus correction based on eigen-vectors
derived from CVs, LFVs and CVs+LFVs and find that the
corrected results are nearly indistinguishable regardless of the
scenario (both data sets individually, SKAT or burden test, meta-
or mega-analysis; Table S2). For example, in the Broad sample
and the SKAT statistic, using no eigenvectors yields lq~1:064
compared to lq~1:03,1:02, and 1.03, derived using CVs, LFVs
and CVs+LFVs, respectively.
Association Analysis of AASC Data
As described previously most analyses of the data use Filter
DpBal to screen called variants. Because one should always be
concerned about the possibility of screening out risk variants by
this filtering process, we first examine the number of genes
exceeding a threshold (i.e. signals) for 3 filters ranging from lenient
(Filter PASS) to stringent (Filter DpBal; Table 2). Applying the test
statistic to the individual data sets we find no large excess of signals
even for the most lenient filter. However, for mega-analysis,
filtering is essential to avoid false positive signals. Consider the
number of genes with p-values less than .001; with baseline
filtering (PASS) we observe a significant excess of such genes
(p~:014), but no excess with any other filters (Table 2). Next,
considering the number of genes with p-values less than .01 the
pattern continues; with baseline filtering (PASS) we observe a
highly significant excess of such genes (pv10{8), but this large
excess is absent for Filter DpBal (Table 2). It is quite likely that the
slight excess of genes with p-values less than .01 after filtering is
due to real, but weak signals in a small set of genes. A candidate
diagnostic for filtering is matching of minor allele count per person
of rare variants (MAC) across platforms (Table 2). However total
MAC is a crude measure of alignment. Diagnostic plots such as
Figure 1B give a more insightful comparison across genes and we
conjecture that a filter chosen to attain good alignment of MAC
across genes is a candidate for successful data harmonization.
MAC should also be similar across cases and controls for most
genes; for Filter DpBal, MAC per person is 330 and 300 in cases
and controls, respectively.
While filtering is beneficial to remove false positives, it has the
potential to remove real signals as well. We explore the effect of
filtering on a particular gene (SCN2A) that has been demonstrated
Table 1. Genomic control l and lq for all tests before and
after PC adjustment.
Broad Baylor Mega Meta
no
PCA PCA
no
PCA PCA
no
PCA PCA
no
PCA PCA
SKAT l 1.197 1.115 1.251 1.163 1.298 1.188 1.322 1.200
SKAT lq 1.064 1.032 1.107 1.046 1.176 1.078 1.145 1.089
Burden l 1.109 1.070 1.146 1.037 1.195 1.107 1.175 1.082
Burden lq 1.059 1.031 1.094 1.027 1.151 1.047 1.104 1.036
Note: These analyses are restricted to the genes that have more than 4 minor
alleles in the samples used in each study. l and lq are calculated based on the
median and the 1st quantile of the p-value distribution, respectively. PC
adjustment is based on the common variants (CVs) eigen-vectors.
doi:10.1371/journal.pgen.1003443.t001
Figure 10. -log10(observed p-values) versus -log10(expected p-values) of SKAT and Burden test for Mega-analysis. Panel (A) shows
SKAT p-values, Panel (B) shows burden test p-values. lq~1:078 and 1.047, for mega SKAT and burden test, respectively.
doi:10.1371/journal.pgen.1003443.g010
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to be an ASD gene based on 3 recurrent de novo loss of function
mutations [4,5]. In the Baylor sample, with Filter PASS we obtain
a suggestive p-value of .009, but many of the observed variants
have high missingness, very low depth and poor balance of alleles.
With Filter MISS the p-value is .033. Finally, with additional
filtering the signal is removed altogether. (Specifically, Filter DpBal
removes 2 putative severe missense mutations [35] and 1 putative
loss of function variant from cases.) There is no evidence of
association in the Broad sample for this gene.
Prior to filtering, a sizable fraction of the loci in which a variant is
called for one subject cannot be called – either heterozygous or
homozygous – for other subjects; it is current practice to remove loci
that have variant calls for some subjects, butw10% of subjects have
missing calls. After filtering (Filter DpBal), .3% of the values are
missing, but the missingness is not evenly distributed across sites or
case/control status (Table 3). Most notably this ‘‘missingness rate’’ in
Baylor cases is twice as high as the missingness in Baylor controls and
90% of the missingness arises from the Baylor site. Although
differential missingness has the potential to cause false positive
associations, differences between cases and controls within each data
set are not so high as to induce an excess of false positive associations
in meta-analysis even in the unfiltered data; however, if we apply
mega-analysis to the unfiltered data, we obtain a significant excess of
genes with p-values v:01 (pv10{4; Table 4). This problem is
remedied by applying Filter DpBal: after filtering, which removes loci
with high rates of missingness, we obtain no excess of small p-values
for the SKAT mega-analysis test statistics. When evaluating this issue
at a finer scale after filtering by looking at the effect of differential
missingness at the gene level, we find no association between the test
statistic and differential missingness (Figure S5).
Neither SKAT nor burden gene-based tests produce a test
statistic exceeding the threshold for exome-wide significance
(:05=20,000~2:5|10{6). Genes with p-valuesv:01 are reported
in Table S3. Note that nearly half of these genes have more rare
variants in controls than cases, suggesting a protective effect, but
we view this as unlikely. Moreover, the evidence is also not
sufficiently compelling to replicate any known ASD gene. To
explore this last issue in more detail we compile a list of genes with
at least two functional de novo mutations identified in the recent
ASD studies [4–6,8] (Table S4), and we examine the 114 ASD
genes cited by [36] as ASD genes (Table S5). For all genes in these
lists we obtain the p-values of SKAT and the burden tests applied
to Broad and Baylor samples separately and jointly by mega-
analysis. None of the genes yield compelling signals, arguing
strongly that our power is insufficient to detect associations with
rare variants without further information to guide our analysis.
Discussion
Studies of the distribution of de novo copy number and sequence
variants in ASD and control subjects invariably find elevated rates
of damaging de novo events in ASD subjects [1–8]. These studies
also invariably find relatively little convergence of de novo events on
particular loci in the human genome. These results are consistent
with only one conclusion about the genetic architecture of ASD,
namely that there are hundreds of genes in the genome that can
affect liability, possibly more. Indeed various statistical analyses of
the data support this conclusion [5,8].
Another common theme of ASD studies is that while de novo
events are rare, they can successfully identify ASD liability genes,
and in general the distribution of rare variation has been a key tool
for gene discovery [37]. By contrast common variation has not yet
proven an effective tool for discovering replicable ASD genes,
although there are tantalizing findings [10].
With these observations in mind the AASC has implemented a
study of rare variation in ASD based on WES [38]. Here we
report on data from almost 2000 ASD subjects and controls. We
find the distribution of rare variation between cases and controls is
Table 2. Number of significant genes (and expected number) under different filters.
Baylor Broad Mega MAC
Filter/a 0:01 0:001 0:01 0:001 0:01 0:001 Ba Br
Filter PASS 97(97) 7(10) 77(78) 10(8) 195(127) 22(13) 462 391
Filter MISS 79(73) 7(7) 77(76) 10(8) 133(113) 11(11) 338 379
Filter DpBal 67(66) 6(7) 69(70) 11(7) 123(106) 11(11) 305 351
Note: These analyses are restricted to the genes that have more than 15 minor alleles in the samples used in each study. MAC columns show the number of minor alleles
called per sample, Ba: Baylor, Br: Broad. Filter PASS includes all variants that score a ‘‘Pass’’ based on GATK, Filter MISS: missingness v10%, Filter DpBal: missingness
v10%, depth ~gw10& balance ~jv0:85 for Baylor, gw10& jv0:75 for Broad.
doi:10.1371/journal.pgen.1003443.t002
Table 3. Counts of missingness per sample after filtering.
Baylor Broad
case control case control
Missing 1,104 561 92 117
Not Missing 124,459 125,002 170,165 170,140
Note: These analyses are for all non-synonymous variants with MAFƒ0:01.
doi:10.1371/journal.pgen.1003443.t003
Table 4. Number of nominally significant genes before and
after filtering.
Meta Mega
Observed Expected Observed Expected
Filter PASS (MAC w0) 156 168 219 168
Filter DpBal (MACw0) 132 156 156 156
Filter PASS (MACw15) 133 127 195 127
Filter DpBal (MACw15) 96 106 123 106
Note: Significance level is 0.01, not corrected for muliple testing. The analyses of
the first two rows are for all genes that have at least one MAC in Baylor and
Broad dataset. The last rows are restricted to the genes that have more than 15
minor alleles after combining Baylor and Broad datasets.
doi:10.1371/journal.pgen.1003443.t004
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remarkably similar, showing that ASD risk genes cannot be
identified in a case-control sample of this size. Indeed, even known
ASD genes showed little association in this study. This finding is in
keeping with other studies of rare variants, but with quite different
phenotypes, supporting the conjecture that rare variant association
studies require large samples [19,39,40]. With respect to the
genetics of ASD, the results are also consistent with the inference
from de novo studies that there must be hundreds genes affecting
liability to ASD [3–6,8]. These results underscore the scale of the
challenges ahead in our effort to discover ASD genes. Large
samples must be amassed and assessed and effective study designs
implemented [41].
To gain insight into the limited power of this study, consider
three scenarios: (A) the gene has 15 variants, each with
MAF~:0025, for which all have odds ratio of 4; (B) the gene
has 20 variants, each with MAF~:005, for which 10 have odds
ratio of 3; and (C) the gene has 40 variants, each with MAF~:005,
for which 30 have odds ratio of 2. We list the required samples size
of each scenario in Table S6 to achieve a power of 50% and 80%
per gene (with a p-value threshold of 10{5). Even though the
power of mega-analysis is only 0.31, 0.11 and 0.06 for our study,
assuming these scenarios were realistic, power would have been
sufficient to discover a fraction of the large number of ASD genes
present in the genome. We conclude that these scenarios do not
describe likely models for risk genes in ASD.
As with GWAS, to assimilate large samples and gain power,
multiple studies must be combined. In the analysis of samples from
multiple studies, meta-analysis, based on Z-scores, has become the
norm for most genetic investigations. This form of meta-analysis
has power equal to mega-analysis for single variant tests [42],
hence it is reasonable to assume that meta-analysis is generally
superior to mega-analysis because the former more easily
accommodates heterogeneity across studies. A notable result from
our study is that these results do not carry over to gene-based tests
such as SKAT. In that setting mega-analysis has considerably
more power than meta-analysis because mega-analysis assesses the
concordance of association for a variant across all sites and then
combines information across all variants within a gene. In this
way, the method separates true signals from false ones and attains
a greater signal to noise ratio. In contrast, meta-analysis combines
information across studies at the gene level and hence can not
assess the pattern of signals at the variant level across sites.
A drawback of mega-analysis is that we encounter challenges
when combining datasets collected across multiple studies, which
can differ in many respects due to the use of different sequencing
platforms and protocols. For instance, these differences lead to
differential coverage by exon and different alignment errors. Even
the best laboratory process has measurement error and these
errors are exacerbated when they differ across batches of samples,
particularly if they differ between cases and controls. For these
reasons caution must be exercised if one is to reap the benefits of
mega-analysis. Indeed, even after careful filtering, heterogeneity
between sites could account for the modest inflation in the
associate test statistics and the genomic control factor after
combining sites via meta- and mega-analysis.
In this study we construct extra filters to ensure that the
distribution of rare variation of the WES data is similar for the two
centers. We find good results filtering called variants by fraction of
missing data, read depth, and balance of alternative to reference
reads. Ideally a filter is tuned by measuring some individuals on
multiple platforms. We tune our filters using subjects measured
twice. If such data are unavailable, however, we find that another
promising approach is to compare minor allele counts (based on
rare variants) per gene. A good filter is one that aims to equilibrate
these quantities.
Even with the most minimal filtering we observe no excess of
positive signals for association within the individual data sets, but
for mega-analysis we observe a great number of positive
associations. These false discoveries are diminished, however,
after filtering. Likewise mega-analysis is more susceptible than
meta-analysis to the impact of differential missingness across
platforms and across case/control status. Indeed, without filtering,
mega-analysis has many false discoveries but meta-analysis did
not. However, using filtered data we find that mega-analysis is
quite robust to differences in missingness rates across platforms
and case/control status, although we recognize that this robustness
could fail for more extreme heterogeneity of missingness. Still our
study has some differences in missingness and yet does not produce
detectable false discoveries. From our analyses we conjecture that
filtering that removes variants with w10% missingness (per data
set) is largely effective.
When combining data sets the effects of population substructure
on association is also a concern due to clustering of rare variants in
ancestry space [40,43]. Even though our case-control samples are
approximately pair-matched by ancestry in the study design, we
find weak evidence of population structure confounding the test of
association. In our data these effects could be mitigated by
regressing out principal components of ancestry using common
variants or low frequency variants. This result supports findings of
[44], but is contrary to other predictions [43]. Thus, although rare
variants tend to be younger, and therefore distinctly clustered in
populations, in our sample estimates of ancestry derived from
common variants capture the major features of the distribution of
rare variants in ancestry space.
In conclusion we find that WES data on nearly 2000 samples
collected for a case-control study are insufficient to discover novel
liability genes for ASD, even after applying efficient methods like
mega-analysis and controlling for ancestry effectively. These
results demonstrate that much larger samples will be required
for effective gene discovery and lend further support to the
prediction that there are hundreds of genes that impact ASD
liability in the human genome.
Methods
Data
The AASC whole-exome sequencing data includes 1039
independent subjects diagnosed with autism spectrum disorders
(ASD). Subjects were selected to be of European ancestry, based
on genetic (eigen-vector) analysis and European origin. Samples
were selected from the Autism Genetic Resource Exchange
(AGRE, research.agree.org), the Autism Simplex Collection
(TASC [45]), National Database for Autism Research (NDAR,
ndar.nih.gov) and the Boston’s Autism Consortium (autism.con-
sortium.org). 870 independent controls were selected from the
NIMH repository (www.nimhgenetics.org) to be of similar ancestry
to cases (Baylor cases: 440 males, 65 females; Baylor controls: 240
males, 251 females: Broad cases: 429 males, 105 females, largely
from the autism Consortium; Broad controls: 177 males, 202
females.) The Broad cases included probands only from trios.
These trios were previously analyzed for de novo variants [5]. De
novo variants were included in these analysis.
To evaluate sequence quality, 7 controls were sequenced at both
centers. The capture/enrichment assays used were Nimblegen
(Baylor) and Agilent (Broad). The Baylor samples were sequenced
using the Solid platform and called with AtlasSNP 2 [30]. The
Broad samples were sequenced using the Illumina platform and
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called with GATK [31]. Standard filters were used as part of both
pipelines to produce calls for SNVs and indels. For details see Text
S1.
In general, the MAF of SNVs matched well for the majority of
the SNVs in the two data sets, but some differed considerably
(Figure S6). One source of differences was the read depth: Broad
reads had greater mean depth and also greater variability than
Baylor reads (Figure S7). Overall counts of variants differed by
platform (Table 5). We utilized additional filters to make these
data sets more compatible. Relying on the validated de novo
variants [5] and 7 overlapping samples we constructed an
additional 3-round filter (see Text S1 and Table S7). First, for
each data set, we excluded the variants that had 10% or more
missing calls. Second, we discarded the variants that had average
depth less than g. Third, we filtered the variants by the quality of
the minor allele call. We defined the balance of depth for each
minor allele call as the reference depth divided by the total depth.
If more than half of the minor allele calls had a balance larger than
j or depth smaller than g, we discarded this variant. Based on
these features we constructed 6 filters denoted by PASS, MISS,
DpBal, B, C and D of increasing stringency. For Filter DpBal,
g~10, j~:75 for the Broad data set and :85 for the Baylor data
set; for Filter B, g~10, j~:75; for Filter C, g~17, j~:66 for the
Broad data set and g~12, j~:75 for the Baylor data set; for Filter
D, g~10, j~:66. If less than half of the minor allele calls had a
balance larger than j, we kept this variant but changed the specific
calls that did not pass the quality threshold from heterozygote to
the common homozygote call.
Two rounds of filtering were performed on called indels. First,
for each data set, we excluded indels with MAF greater than 1% or
more than 10% missing calls. Second, we excluded indels that had
more than six calls in one data set and none in the other data set.
Statistical Analysis
For n subjects sequenced, let y~(y1,:::,yn)’ denote the vector of
phenotypes. For a gene with d rare variants let Gi~(Gi1, . . . ,Gid )’
be the d-dimensional genotype vector. For dichotomous pheno-
types we consider a logistic model:
logitP(yi~1)~a0za
0Xizb0Gi, ð1Þ
where a0 is the intercept, a is a vector of regression coefficients for
fixed covariates Xi such as sex and ancestry, and b is the vector of
log odds ratios for the genetic variants. For analytical purposes
only we also discuss the corresponding linear model for continuous
phenotypes:
yi~a0za
0Xizb0Gizei, ð2Þ
where i*N(0,s2). Without loss of generality, we assume s~1.
We want to test the null hypothesis H0 : b1~b2~   ~bd~0.
One way to increase the power of the test is to assume that
b1~b2~   ~bd~bc and test if bc~0 [46]. Tests of this
hypothesis are often called burden tests. To add prior information
to this test, the weighted sum test has been proposed [22]. The
idea of weighted sum test is to use Giv~(v1Gi1,:::vdGid ) rather
than Gi~(Gi1,:::Gid ) in model (1) so that biologically more
plausible risk variants have larger weights in the test statistic. In
our study, we use the weighted sum test with weightsffiffiffiffiffi
vj
p
~Beta(pj ,1,25), where pj is the MAF of jth variant. To
implement the test, the genotypes Gi in model (Eqn. 1) are
replaced by a single composite term Civ, which is the weighted
sum of the genotype values of all rare variants Civ~
Pd
j~1 vjGij .
To assess significance of Civ as a predictor, we use the score test.
There are drawbacks to a burden test. It assumes that all rare
variants in the gene have the same direction and magnitude of
association. In reality, variants can be damaging, protective, or
have no effect, potentially reducing the power of the test. To
overcome these drawbacks, the C-alpha test [25] has been
proposed. The test is sensitive to unusual patterns in the
distribution of rare variants across cases and controls. It has good
power if most of the copies of a rare variant occur in cases (or
controls), yet unlike the burden test, this pattern can vary across
SNVs. SKAT [26] is a generalization of the C-alpha test. It has the
advantage of readily incorporating covariates, but without
covariates it reduces to the same form as C-alpha. This statistic
is based on the generalized linear model (Eqn. 1 or 2), with
random effects for the bj ’s, which are assumed to follow an
arbitrary distribution with mean zero and variance vjt [47]. The
test statistic is the score test for H0 : t~0, which is of the form
Q~(y{m^)TK(y{m^),
where K=GWG’ is the kernel matrix, W~diag(v1, . . . ,vd ) is a
weight matrix, and m^~logit{1(a^0zXa^) for the logistic model (1)
and m^~(a^0zXa^) for the linear model (2). The SKAT statistic can
also be expressed in terms of the individual score tests for
evaluating bj~0 for each of the d variants; let Sj~Gj’(y{m^),
j~1, . . . ,d , then
Q~
Xd
j~1
vjS
2
j :
The null distribution of Q is approximately a linear combination
of x2 distributions,
Q*
X
i~1
lix
2
1,i: ð3Þ
The SKAT p-values can be obtained by applying Davies exact
method [48] to the data and inverting the characteristic function
of Q.
Meta- Versus Mega-Analysis
Suppose we have samples from two (or more) datasets. To fix
ideas, consider two data sets, D1 and D2 where n1 and n2 are the
sample sizes, respectively. To perform meta-analysis using the
weighted Z-score approach, first compute Zk~W
{1(p-valuek),
where the p-values are obtained for each data set k~1,2
independently, and W is the standard normal distribution function.
Then the meta-analysis p-value is computed from W(Z), where
Table 5. Counts of non-synonymous variants in Baylor and
Broad before filtering.
Single Double RVs LFVs CVs total
Baylor 193,281 22,355 29,363 9800 14,159 268,958
Broad 119,648 17,628 27,644 9996 16,327 191,243
Note: Single: count of singletons; Double: count of doubletons; RVs: count of
variants with MAFƒ0:01 and not singletons or doubletons; LFVs: count of
variants with MAF w0:01&ƒ0:05; CVs: count of variants with MAF w0:05.
doi:10.1371/journal.pgen.1003443.t005
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Z~
n1Z1zn2Z2ffiffiffiffiffiffiffiffiffiffiffiffiffiffi
n21zn
2
2
q :
When applied to the SKAT test, this statistic combines informa-
tion at the gene level without consideration of the directionality of
any single variant effects.
We formally consider the SKAT test statistics in meta- and
mega-analysis by deriving a closed form expression for the power
of meta- and mega-analysis under restricted conditions. In the
Results we show via simulations that the results hold more
generally. Analysis is greatly simplified by choosing weights
vj~f2pj(1{pj)g{1, a choice suggested in [22]. This weight is
equivalent to scaling Gij as
Tij~(Gij{2pj)=
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
2pj(1{pj)  n
p
,
where pj is the MAF of the jth variant. For the following
calculations we also assume no linkage disequilibrium (LD)
between rare variants [49,50]. Consequently we have
E
X
i
TijTik
" #
~Ifj~kg:
In the Results we show that this assumption appears to be
reasonable in the AASC data. Under these conditions and
assuming there are no covariates, we note that Q*x2d (d), with
d~
X
k
2pk(1{pk)nb
2
k, ð4Þ
for the linear model (Eqn. 2), and
d&
X
k
1
8
pk(1{pk)nb
2
k, ð5Þ
for the logistic model (Eqn. 1; see Text S1).
It follows that the mega-SKAT statistic Qg*x2d (dg), where the
experiment-wise non-centrality parameter is the sum of non-
centrality parameters from the individual studies: dg~d1zd2.
Hence, when combining 2 studies, with sample sizes n1 and n2, in
which the k’th variant has log odds ratio bk, the contribution to
the signal is proportional to
2pk(1{pk)(n1zn2)b
2
k:
Notice that this term is approximately equal to the number of
realizations of the variants in the pooled data (m in the example
above) times the square of the log odds ratio. For rare variants the
number of realizations tends to be very small, emphasizing that
large samples are essential to gain good power.
In a comparison of the power of meta- and mega-analysis we
assume data sets D1 and D2 have the same sample size and rare
variants at the same locations. Furthermore, building on our
analysis above, we assume the individual test statistics from the two
samples are distributed as Q1*x2d (d) and Q2*x
2
d (d). Under a-
level type I error, the power function of weighted z-score meta-
analysis and the power function of mega-analysis can be
approximated as given in Text S1 (Eqn. S3–S4). The derived
expressions are complex, but from Figure 2 we see, regardless of
the degrees of freedom, mega-analysis has greater power than
meta-analysis.
To gain more analytical insight, consider a gene for which each
sample has sufficient coverage to detect all rare variants and that a
total of d rare variants are observed. Let y1 and y2 be the
corresponding phenotype vectors and G1j and G2j the genotype
vectors for variants j, j~1,:::,d . Furthermore, let S1j and S2j
denote the jth variant scores corresponding to D1 and D2. Next
let’s look at the test statistics for mega-analysis Qg :
Qg~
Xd
j~1
vj ½(G’1j ,G’2j)((y1,y2){(m^1,m^2))2
~
Xd
j~1
vj ½G’1j(y1{m^1)zG’2j(y2{m^2)2
~Q1zQ2z
Xd
j~1
½2vjG’1j(y1{m^1) G’1j(y2{m^2)
~Q1zQ2z
Xd
j~1
2vjS1jS2j :
Under the alternative hypothesis, the per-variant scores S1j and
S2j corresponding to j’th causal variant tend to have the same sign;
positive for risk variants and negative for protective variants.
Under the null hypothesis these per-variant score statistics are
uncorrelated and tend to cancel each other out, on average.
Consequently the final term in the expansion above tends to be
positive under the alternative hypothesis and close to zero under
the null.
In the Text S1 we find that the information captured by the meta-
analysis statistic is approximated by the two lead terms
(Q1zQ2*x22d (d1zd2)). Thus this expansion reveals why mega-
analysis is more powerful than meta-analysis for quadratic test
statistics such as SKAT. Mega-analysis cancels out false signals that
differ in sign. Meta-analysis is restricted to gene level information
and hence cannot account for directionality. The strength of the
signal over a gene is determined by two factors: the sum of the per-
variant contributions to the signal, versus the number of degrees of
freedom. Both meta and mega-analysis assimilate the same signal
(d1zd2), but the strength of the signal for meta-analysis is
apportioned over more degrees of freedom, effectively diminishing
the power. For mega-analysis, the degrees of freedom increase only
if the rare variants occur at different locations in the separate
studies. The power advantage of mega-analysis is most pronounced
when the rare variants accumulate at common locations across data
sets. meta-analysis is not able to assimilate information within a
variant across data sets as efficiently.
Supporting Information
Figure S1 PCA from common variants, low frequency variants
and both type of variants for Baylor samples. Eigen-vectors are
obtained by applying PCA to all common variants that have no
missingness (14,702 variants) (A), all low frequency variants that
have no missingness (8783 variants) (B), and both type of variants
(C). The colors are obtained by clustering individuals based on
their coordinates in panel (A) using model based clustering [51].
(A) and (B) are the first eigen-vector versus second eigen-vector for
Baylor samples. (C) is the first eigen-vector versus second eigen-
vector for Baylor samples.
(TIF)
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Figure S2 PCA of Baylor and Broad samples together. first
eigen-vector versus second eigen-vector for Broad and Baylor
samples.
(TIF)
Figure S3 Histogram of p-values for SKAT and Burden Test.
(A) and (B) are SKAT p-values for Broad and Baylor samples,
respectively. (C) and (D) are Burden test p-values for Broad and
Baylor samples, respectively. Green vertical lines are the 25%,
50% and 75% quantiles of p-values.
(TIF)
Figure S4 Distribution of the genomic control factor l. By
permuting case/control status 100 times the distribution of l is
obtained based on the 1000 largest genes. The red line shows the
mean of the permutation distribution and the green line shows l
obtained from the data using (A) Broad SKAT p-values obtained
without eigenvectors; (B) Broad SKAT p-values, with CVs
eigenvectors, (C) Broad SKAT p-values, with LFVs eigenvectors;
and (D) Broad SKAT p-values, with CVs plus LFVs eigenvectors.
(TIF)
Figure S5 P-values versus Missingness. We used 5500 genes to
make this plot. For each gene, we calculate the -log 10 p-values
and the odds ratio of missingness in case and control. The red line
is the fitted line of these 5500 observations.
(TIF)
Figure S6 MAF Comparison: Baylor versus Broad. We compare
the MAF for 72,758 shared non-synonymous variants in the two
data sets.
(TIF)
Figure S7 Depth Comparison: Baylor versus Broad. We
compare the average sample depth for all non-synonymous
variants in the two data sets.
(TIF)
Table S1 Comparison of seven individuals called by both Baylor
and Broad under different filters.
(PDF)
Table S2 Genomic control l and lq based on different types of
PC adjustment.
(PDF)
Table S3 Genes with p-valuev0:01 from the SKAT or Burden
Test.
(XLSX)
Table S4 The p-values of genes which have two or more de novo
nonsense or missense mutations as reported in [5].
(XLSX)
Table S5 The p-values of 114 ASD genes.
(XLSX)
Table S6 The required sample sizes by applying meta- and
mega-analysis.
(PDF)
Table S7 Classification tree results for heterozygote calls.
(PDF)
Text S1 Additional Information Regarding Methods. Part A
gives additional information about sequencing, including data
generation and quality control. Part B gives the mathematical
exposition of mega- and meta-analysis. Part C provides details for
association analysis.
(PDF)
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